Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8388628 | 0.82 | GPR84 (0.51) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL24145251 | 0.81 | GPR84 (0.65) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL13789952 | 0.81 | GPR84 (0.65) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL12633664 | 0.80 | GPR84 (0.68) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL9262621 | 0.80 | GPR84 (0.68) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL12633116 | 0.80 | GPR84 (0.68) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL15033119 | 0.79 | GPR84 (0.67) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL30579357 | 0.79 | GPR84 (0.67) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL735351 | 0.79 | GPR84 (0.67) | GPR84FFAR1HTR2AHTR2CHTR2B | |
| SCHEMBL29012500 | 0.79 | GPR84 (0.49) | GPR84FFAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250242029-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| WO-2025080946-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-115894606-A | RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114786777-A | RAS inhibitors | 锐新医药公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465643-B2 | Ras inhibitors | KRAS, NRAS, HRAS | GPR84 3672/4885FFAR1 4559/4885HTR2A 4747/4885 |
| US-20250242029-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GPR84 3672/4885FFAR1 4559/4885HTR2A 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.